NASDAQ · PBH
Healthcare · Medical - Distribution
$51.38
Up+$0.06 (+0.12%)
Updated Aug 15, 2026, 8:21 AM
SID Score
6.4/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 21 trading sessions · Daily adjusted prices
PBH closed at $51.38 after 21 trading sessions, up 2.92% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $51.07 | $52.00 | $50.355 | $51.38 | 487.11K |
| Aug 13, 2026 | $52.77 | $52.895 | $50.70 | $51.32 | 643.82K |
| Aug 12, 2026 | $54.50 | $54.72 | $52.25 | $52.27 | 645.79K |
| Aug 11, 2026 | $52.87 | $53.75 | $52.3854 | $53.60 | 516.77K |
| Aug 10, 2026 | $54.31 | $54.87 | $52.635 | $53.00 | 625.2K |
| Aug 7, 2026 | $54.95 | $55.45 | $54.145 | $54.85 | 597.75K |
| Aug 6, 2026 | $55.40 | $55.99 | $52.05 | $54.43 | 837.7K |
| Aug 5, 2026 | $52.49 | $53.215 | $51.43 | $52.98 | 610.2K |
| Aug 4, 2026 | $50.95 | $52.78 | $50.59 | $52.00 | 1.07M |
| Aug 3, 2026 | $51.20 | $52.6604 | $51.07 | $51.92 | 832.27K |
| Jul 31, 2026 | $49.46 | $50.4609 | $49.03 | $50.22 | 392.95K |
| Jul 30, 2026 | $51.09 | $51.09 | $49.78 | $49.95 | 392.33K |
| Jul 29, 2026 | $51.20 | $52.49 | $51.20 | $52.19 | 386.3K |
| Jul 28, 2026 | $51.34 | $52.53 | $50.185 | $51.72 | 439.54K |
| Jul 27, 2026 | $50.36 | $51.28 | $49.58 | $50.40 | 435.84K |
| Jul 24, 2026 | $49.36 | $50.39 | $48.92 | $49.66 | 350.48K |
| Jul 23, 2026 | $48.89 | $49.55 | $48.25 | $48.94 | 542.94K |
| Jul 22, 2026 | $49.70 | $49.82 | $48.60 | $49.02 | 362.55K |
| Jul 21, 2026 | $49.51 | $51.06 | $48.31 | $49.03 | 704.15K |
| Jul 20, 2026 | $49.85 | $50.93 | $48.71 | $50.41 | 772.74K |
| Jul 17, 2026 | $50.51 | $51.57 | $48.88 | $49.92 | 443.13K |
The latest Smart Investors Daily articles mentioning PBH.
PBH research
Company profile and research snapshot.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 15, 2026 | Canaccord Genuity | Buy | — |
| May 14, 2026 | Oppenheimer | Perform | — |
| May 7, 2026 | Oppenheimer | Outperform | — |
| Feb 2, 2026 | Jefferies | Hold | — |
| Nov 7, 2025 | Canaccord Genuity | Buy | — |
No generated briefing is available yet.
Yahoo · Aug 9, 2026
Prestige Consumer Healthcare (NYSE:PBH) reported first-quarter fiscal 2027 revenue growth of 6.5%, supported by broad-based category strength, the initial contribution from its Breathe Right acquisition and retailer order timing. The company raised its reported full-year outlook to incorporate Breat
Yahoo · Aug 8, 2026
In early August 2026, Prestige Consumer Healthcare reported fiscal 2027 first‑quarter revenue of US$265.71 million, up from US$249.53 million a year earlier, and raised its full‑year 2027 revenue outlook to US$1.29 billion–US$1.32 billion and projected GAAP diluted EPS of US$4.18–US$4.28, reflecting the addition of the Breathe Right and LaCorium businesses. While recent acquisitions are expected to contribute meaningfully to revenue and earnings, the quarter also showed lower net income and...
Yahoo · Aug 7, 2026
Prestige Consumer's Q1 earnings and revenues outpace estimates as acquisitions boost its fiscal 2027 outlook despite margin pressure.
Yahoo · Aug 6, 2026
PBH exceeds expectations with 6.5% sales growth, completes Breathe Right integration, and raises full-year EPS guidance.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PBH.
